ID   LS180
AC   CVCL_0397
SY   LS-180; LS 180; Laboratory of Surgery 180
DR   BTO; BTO:0001609
DR   CLO; CLO_0007394
DR   CLO; CLO_0007404
DR   EFO; EFO_0006640
DR   MCCL; MCC:0000291
DR   CLDB; cl3262
DR   CLDB; cl3263
DR   CLDB; cl7120
DR   AddexBio; C0009006/56
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CL-187
DR   ATCC; CCL-187
DR   BCRC; 60100
DR   BioGRID_ORCS_Cell_line; 564
DR   BioSample; SAMN03472231
DR   BioSample; SAMN10988327
DR   cancercelllines; CVCL_0397
DR   CCRID; 1101HUM-PUMC000284
DR   Cell_Model_Passport; SIDM00680
DR   ChEMBL-Cells; CHEMBL4295398
DR   ChEMBL-Targets; CHEMBL4296462
DR   ColonAtlas; LS180
DR   Cosmic; 869793
DR   Cosmic; 913893
DR   Cosmic; 948854
DR   Cosmic; 995378
DR   Cosmic; 1043820
DR   Cosmic; 1184098
DR   Cosmic; 1187311
DR   Cosmic; 1466819
DR   Cosmic; 1479574
DR   Cosmic; 1708417
DR   Cosmic; 2052595
DR   Cosmic; 2301998
DR   Cosmic; 2667976
DR   Cosmic; 2727472
DR   Cosmic-CLP; 998189
DR   DepMap; ACH-000957
DR   ECACC; 87021202
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 998189
DR   GEO; GSM206520
DR   GEO; GSM513928
DR   GEO; GSM514299
DR   GEO; GSM741271
DR   GEO; GSM784017
DR   GEO; GSM827346
DR   GEO; GSM887279
DR   GEO; GSM888354
DR   GEO; GSM1346847
DR   GEO; GSM1374634
DR   GEO; GSM1374635
DR   GEO; GSM1374636
DR   GEO; GSM1448139
DR   GEO; GSM1670060
DR   IARC_TP53; 21766
DR   ICLC; HTL01016
DR   IZSLER; BS TCL 82
DR   LiGeA; CCLE_023
DR   LINCS_LDP; LCL-1183
DR   Lonza; 348
DR   MetaboLights; MTBLS227
DR   NCBI_Iran; C508
DR   PharmacoDB; LS180_859_2019
DR   PRIDE; PXD005235
DR   PRIDE; PXD005354
DR   PRIDE; PXD005355
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0397
DR   PubChem_Cell_line; CVCL_0397
DR   Wikidata; Q54903057
RX   Patent=US4228236;
RX   PubMed=1262041;
RX   PubMed=6652615;
RX   PubMed=7370982;
RX   PubMed=9515795;
RX   PubMed=10737795;
RX   PubMed=11314036;
RX   PubMed=12615714;
RX   PubMed=16418264;
RX   PubMed=18258742;
RX   PubMed=20215515;
RX   PubMed=20570890;
RX   PubMed=20606684;
RX   PubMed=22460905;
RX   PubMed=23272949;
RX   PubMed=24755471;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25926053;
RX   PubMed=26537799;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28854368;
RX   PubMed=29101300;
RX   PubMed=29444439;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Group: Patented cell line.
CC   Part of: AstraZeneca Colorectal cell line (AZCL) panel.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: NCI RAS program mutant KRAS cell line panel.
CC   Part of: RAS genetic alteration cell panel (ATCC TCP-1031).
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CL-187.
CC   Population: Caucasian.
CC   Doubling time: 72 hours (PubMed=7370982).
CC   HLA typing: A*02; B*13,50 (ATCC=CL-187).
CC   HLA typing: A*30:01,30:01; B*07:12,15:50; C*04:01,06:02 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=24755471; PubMed=25926053; PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (PubMed=12615714).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Homozygous (PubMed=24755471; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=20570890; PubMed=24755471; ATCC).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=20570890; PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (PubMed=12615714).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16418264).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: N-glycan profiling.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.1%; Native American=0%; East Asian, North=0.33%; East Asian, South=0.79%; South Asian=7.05%; European, North=35.25%; European, South=55.48% (PubMed=30894373).
CC   Discontinued: ATCC; CCL-187; probable.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
CC   Cell type: Epithelial cell of colon; CL=CL_0011108.
ST   Source(s): AddexBio; ATCC; CCRID; Cosmic-CLP; PubMed=25877200; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 10,12 (CCRID)
ST   CSF1PO: 10,13 (AddexBio; ATCC; Cosmic-CLP; PubMed=25877200; PubMed=25926053)
ST   D13S317: 10
ST   D16S539: 11,12 (CCRID)
ST   D16S539: 11,13 (AddexBio; ATCC; Cosmic-CLP; PubMed=25877200; PubMed=25926053)
ST   D18S51: 11,13
ST   D19S433: 14,15
ST   D21S11: 29,31
ST   D2S1338: 18,22
ST   D3S1358: 15,17
ST   D5S818: 10,15
ST   D7S820: 9.3,11 (AddexBio; ATCC; Cosmic-CLP; PubMed=25877200)
ST   D7S820: 10,11 (PubMed=25926053)
ST   D7S820: 10.3,11 (CCRID)
ST   D8S1179: 12,16
ST   FGA: 21,22
ST   Penta D: 10
ST   Penta E: 15,16
ST   TH01: 6,7
ST   TPOX: 8,9
ST   vWA: 15,18
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 44
//
RX   Patent=US4228236;
RA   Jakstys M.M., Tom B.H., Kahan B.D.;
RT   "Process of producing carcinoembryonic antigen.";
RL   Patent number US4228236, 14-Oct-1980.
//
RX   PubMed=1262041; DOI=10.1007/BF02796440;
RA   Tom B.H., Rutzky L.P., Jakstys M.M., Oyasu R., Kaye C.I., Kahan B.D.;
RT   "Human colonic adenocarcinoma cells. I. Establishment and description
RT   of a new line.";
RL   In Vitro 12:180-191(1976).
//
RX   PubMed=6652615; DOI=10.1016/0165-4608(83)90092-4;
RA   Chen T.-R., Hay R.J., Macy M.L.;
RT   "Intercellular karyotypic similarity in near-diploid cell lines of
RT   human tumor origins.";
RL   Cancer Genet. Cytogenet. 10:351-362(1983).
//
RX   PubMed=7370982;
RA   Rutzky L.P., Kaye C.I., Siciliano M.J., Chao M., Kahan B.D.;
RT   "Longitudinal karyotype and genetic signature analysis of cultured
RT   human colon adenocarcinoma cell lines LS180 and LS174T.";
RL   Cancer Res. 40:1443-1448(1980).
//
RX   PubMed=9515795;
RA   Sparks A.B., Morin P.J., Vogelstein B., Kinzler K.W.;
RT   "Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal
RT   cancer.";
RL   Cancer Res. 58:1130-1134(1998).
//
RX   PubMed=10737795; DOI=10.1073/pnas.97.7.3352;
RA   Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J.,
RA   Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.;
RT   "APC mutations in sporadic colorectal tumors: a mutational 'hotspot'
RT   and interdependence of the 'two hits'.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).
//
RX   PubMed=11314036; DOI=10.1038/sj.onc.1204211;
RA   Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L.,
RA   Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R.,
RA   Minna J.D.;
RT   "Searching for microsatellite mutations in coding regions in lung,
RT   breast, ovarian and colorectal cancers.";
RL   Oncogene 20:1005-1009(2001).
//
RX   PubMed=12615714;
RA   Hempen P.M., Zhang L., Bansal R.K., Iacobuzio-Donahue C.A.,
RA   Murphy K.M., Maitra A., Vogelstein B., Whitehead R.H., Markowitz S.D.,
RA   Willson J.K.V., Yeo C.J., Hruban R.H., Kern S.E.;
RT   "Evidence of selection for clones having genetic inactivation of the
RT   activin A type II receptor (ACVR2) gene in gastrointestinal cancers.";
RL   Cancer Res. 63:994-999(2003).
//
RX   PubMed=16418264; DOI=10.1073/pnas.0510146103;
RA   Liu Y., Bodmer W.F.;
RT   "Analysis of P53 mutations and their expression in 56 colorectal
RT   cancer cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
//
RX   PubMed=18258742; DOI=10.1073/pnas.0712176105;
RA   Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.;
RT   "Cell growth, global phosphotyrosine elevation, and c-Met
RT   phosphorylation through Src family kinases in colorectal cancer
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192;
RA   Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S.,
RA   Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M.,
RA   Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M.,
RA   Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.;
RT   "Genomic and biological characterization of exon 4 KRAS mutations in
RT   human cancer.";
RL   Cancer Res. 70:5901-5911(2010).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23272949; DOI=10.1186/1755-8794-5-66;
RA   Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A.,
RA   Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A.,
RA   Orphanides G., French T., Wessels L.F.A.;
RT   "Subtypes of primary colorectal tumors correlate with response to
RT   targeted treatment in colorectal cell lines.";
RL   BMC Med. Genomics 5:66.1-66.15(2012).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=26537799; DOI=10.1074/mcp.M115.051235;
RA   Holst S., Deuss A.J.M., van Pelt G.W., van Vliet S.J.,
RA   Garcia-Vallejo J.J., Koeleman C.A.M., Deelder A.M., Mesker W.E.,
RA   Tollenaar R.A., Rombouts Y., Wuhrer M.;
RT   "N-glycosylation profiling of colorectal cancer cell lines reveals
RT   association of fucosylation with differentiation and caudal type
RT   homebox 1 (CDX1)/villin mRNA expression.";
RL   Mol. Cell. Proteomics 15:124-140(2016).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010;
RA   Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C.,
RA   Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M.,
RA   Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R.,
RA   Guinney J., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.;
RT   "Genomic determinants of protein abundance variation in colorectal
RT   cancer cells.";
RL   Cell Rep. 20:2201-2214(2017).
//
RX   PubMed=29101300; DOI=10.15252/msb.20177701;
RA   Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S.,
RA   Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S.,
RA   Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J.,
RA   Weichert W., Knapp S., Feller S.M., Kuster B.;
RT   "Pharmacoproteomic characterisation of human colon and rectal
RT   cancer.";
RL   Mol. Syst. Biol. 13:951-951(2017).
//
RX   PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051;
RA   Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W.,
RA   Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A.,
RA   Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E.,
RA   Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C.,
RA   Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H.,
RA   McCormick F.;
RT   "Differential effector engagement by oncogenic KRAS.";
RL   Cell Rep. 22:1889-1902(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//